JUL 20, 2019 7:27 AM PDT

New hope for ovarian cancer

Ovarian cancer affects roughly 1 in 78 women and although survival rates are high (over 90%) with early diagnosis, we currently do not have a way to test for early detection and thus early diagnosis only occurs in around 20% of cases. That means that most women don’t discover their disease until it has already started spreading, making it much harder to treat. But new research focusing on high-grade serous ovarian cancer, which is the most common form of ovarian cancer, offers hope for alternative treatments.

The research was published recently in the journal Molecular Cancer Research and suggests that blocking a particular enzyme called isocitrate dehydrogenase 1 (IDH1) could deter the proliferation of high-grade serous ovarian cancer cells, essentially by putting the cancer cells into early senescence and making it impossible for them to grow and multiply.

"One of the biggest problems of cancer cells," says senior study author Katherine M. Aird Ph.D., assistant professor of cellular and molecular physiology at Penn State College of Medicine in Hershey, PA, "is they can grow forever without stimulus. By inducing senescence, the cells can no longer divide and grow," she adds.

Dr. Aird and her colleagues arrived at this conclusion after analyzing the ways that healthy and cancerous fallopian tube cells use sugar. Implementing mass spectrometry, the team found that while the cancer cells tended to use sugar in the citric acid cycle, the healthy cells usually converted sugar to lactate through aerobic glycolysis.

This is exactly why many cancer treatments target glycolysis – but in the process, these treatments risk damaging healthy cells as well. The IDH1 enzyme, on the other hand, is critical to the citric acid cycle, and blocking it could provide alternative treatment methods that specifically target cancer cells.

New research could lead to alternative treatments for ovarian cancer. Photo: Pixabay

As Medical News Today reports, the need for new treatments can target later stages of the ovarian cancer is of utmost urgency. “Around 70% of those with high-grade serous ovarian cancer will experience relapse because the cancer has a tendency to develop resistance to chemotherapy. There is an urgent need for new approaches to treating this disease.”

Dr. Aird hopes this finding will lead to those alternative treatments, saying "One of our long term goals is to try and repurpose this already approved drug as a treatment for this form of ovarian cancer.” According to her, the FDA has already approved a drug that specifically targets the IDH1 enzyme.

Sources: Medical News Today, Molecular Cancer Research

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUL 28, 2020
Clinical & Molecular DX
Cancer Diagnostics Go Skin Deep
JUL 28, 2020
Cancer Diagnostics Go Skin Deep
The average adult human has between 16 and 22 square feet of skin. This multifaceted organ serves a multitude of functio ...
JUL 25, 2020
Cancer
Researchers use algorithm to develop comprehensive list of pediatric cancer-causing mutations
JUL 25, 2020
Researchers use algorithm to develop comprehensive list of pediatric cancer-causing mutations
A breakthrough study published recently in Science Advances reports the creation of a list of mutations in the noncoding ...
AUG 07, 2020
Cancer
Using organoids to improve chemotherapy for advanced stages of colon and appendiceal cancer
AUG 07, 2020
Using organoids to improve chemotherapy for advanced stages of colon and appendiceal cancer
New research published in the journal Annals of Surgical Oncology uses organoids to finetune chemotherapies that tr ...
SEP 02, 2020
Cancer
New contrast dyes detect cancer using tatoo ink
SEP 02, 2020
New contrast dyes detect cancer using tatoo ink
Researchers have developed new cancer detection agents in the form of contrast dyes from tattoo ink. The results of thes ...
SEP 14, 2020
Genetics & Genomics
Why Defects in One Gene Can Lead to Cancer in Kids
SEP 14, 2020
Why Defects in One Gene Can Lead to Cancer in Kids
While they may occur in adults, a rare, aggressive type of brain cancer called atypical teratoid rhabdoid tumors tend to ...
SEP 13, 2020
Cancer
Should we be treating kidney cancer differently?
SEP 13, 2020
Should we be treating kidney cancer differently?
New research published in the journal Clinical Cancer Research is questioning how we treat kidney tumors. According ...
Loading Comments...